Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives
Frontiers in Medicine,
Journal Year:
2025,
Volume and Issue:
12
Published: Jan. 22, 2025
Parkinson’s
disease
is
a
progressive
neurodegenerative
that
destroys
substantia
nigra
dopaminergic
neurons,
causing
tremors,
bradykinesia,
rigidity,
and
postural
instability.
Current
treatment
approaches
primarily
focus
on
symptom
management,
employing
pharmacological,
non-pharmacological,
surgical
methods.
However,
these
treatments
often
result
in
fluctuating
symptoms,
side
effects,
progression.
Here,
the
authors
have
reviewed
emerging
field
of
nanomedicine
as
promising
path
for
treatment,
emphasizing
its
potential
to
overcome
limitations
traditional
therapies.
Nanomedicine
utilizes
nanoparticles
targeted
drug
delivery,
leveraging
their
small
size
high
surface
area
volume
ratio
cross
blood-brain
barrier
deliver
therapeutic
agents
directly
affected
brain
regions.
Various
nanoparticles,
including
lipid-based,
polymeric,
metallic,
carbon-based,
shown
treatment.
Additionally,
nanocarrier
systems
like
liposomes,
nanogels,
dendrimers,
solid
lipid
offer
controlled
sustained
release
agents,
enhancing
bioavailability
reducing
effects.
This
review
provides
insights
into
pathophysiology
disease,
highlighting
mechanisms
neurodegeneration,
role
alpha-synuclein,
disruption
pathways.
It
further
discusses
application
gene
therapy
conjunction
with
interventions.
Language: Английский
Assessment of the In Vitro Biological Activities of Schiff Base-Synthesized Copper Oxide Nanoparticles as an Anti-Diabetic, Anti-Alzheimer, and Anti-Cancer Agent
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 180 - 180
Published: Feb. 1, 2025
Background/Objectives:
Numerous
diseases
such
as
diabetes,
Alzheimer’s
disease,
and
cancer
have
spread
in
the
whole
world,
especially
Arab
world.
Also,
various
applications
of
Schiff-base
functionalized
nanoparticles
copper
oxide
(CuO-NPs)
therapeutic
been
discovered.
Thus,
current
research
highlights
(i)
synthesis
produced
with
a
Schiff
base
(SB)
serving
capping
agent
during
their
(ii)
assessment
vitro
biological
activities
base-synthesized
(SB-CuO-NPs)
(SB).
Methods:
SB-CuO-NPs
were
characterized
using
ultraviolet-visible
(UV-Vis)
spectroscopy,
zeta
potential,
DLS
analysis,
transmission
electron
microscope
(TEM).
It
also
focuses
on
assessing
activities,
including
antioxidant,
scavenging,
anti-diabetic,
anti-Alzheimer,
anti-arthritic,
anti-inflammatory,
cytotoxic
enzymes
inhibitory
methods
described
literature.
Results:
The
results
compared
those
SB.
demonstrated
superior
when
to
SB
from
which
they
produced.
Conclusions:
this
investigation
concluded
that
CuO-NPs,
synthesized
an
alternative
agent,
exhibited
enhanced
efficacy
relative
original
In
future,
efficiency
against
Alzheimer’s,
will
be
assessed
experimental
animals
(in
vivo).
Language: Английский
Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer’s, Parkinson’s, and ALS
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(23), P. 12613 - 12613
Published: Nov. 24, 2024
Neurodegenerative
diseases,
such
as
Alzheimer's,
Parkinson's,
ALS,
and
Huntington's,
remain
formidable
challenges
in
medicine,
with
their
relentless
progression
limited
therapeutic
options.
These
diseases
arise
from
a
web
of
molecular
disturbances-misfolded
proteins,
chronic
neuroinflammation,
mitochondrial
dysfunction,
genetic
mutations-that
slowly
dismantle
neuronal
integrity.
Yet,
recent
scientific
breakthroughs
are
opening
new
paths
to
intervene
these
once-intractable
conditions.
This
review
synthesizes
the
latest
insights
into
underlying
dynamics
neurodegeneration,
revealing
how
intertwined
pathways
drive
course
diseases.
With
an
eye
on
most
promising
advances,
we
explore
innovative
therapies
emerging
cutting-edge
research:
nanotechnology-based
drug
delivery
systems
capable
navigating
blood-brain
barrier,
gene-editing
tools
like
CRISPR
designed
correct
harmful
variants,
stem
cell
strategies
that
not
only
replace
lost
neurons
but
foster
neuroprotective
environments.
Pharmacogenomics
is
reshaping
treatment
personalization,
enabling
tailored
align
individual
profiles,
while
diagnostics
biomarkers
ushering
era
early,
precise
disease
detection.
Furthermore,
novel
perspectives
gut-brain
axis
sparking
interest
mounting
evidence
suggests
microbiome
modulation
may
play
role
reducing
neuroinflammatory
responses
linked
neurodegenerative
progression.
Taken
together,
advances
signal
shift
toward
comprehensive,
personalized
approach
could
transform
care.
By
integrating
techniques,
this
offers
forward-looking
perspective
future
where
treatments
aim
just
manage
symptoms
fundamentally
alter
progression,
presenting
renewed
hope
for
improved
patient
outcomes.
Language: Английский
Nanobiotechnology Unveils the Power of Probiotics: A Comprehensive Review on the Synergistic Role of Probiotics and Advanced Nanotechnology in Enhancing Geriatric Health.
Cureus,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 12, 2025
The
geriatric
population,
comprising
ages
65
and
above,
encounters
distinct
health
obstacles
because
of
physiological
changes
heightened
vulnerability
to
diseases.
New
technologies
are
being
investigated
tackle
the
intricate
requirements
this
population.
Recent
advancements
in
probiotics
nanotechnology
offer
promising
strategies
enhance
by
improving
nutrient
absorption,
modulating
gut
microbiota,
delivering
targeted
therapeutic
agents.
Probiotics
play
a
crucial
role
maintaining
homeostasis,
reducing
inflammation,
supporting
metabolic
functions.
However,
challenges
such
as
limited
viability
efficacy
harsh
gastrointestinal
conditions
hinder
their
potential.
Advanced
can
overcome
these
constraints
enhancing
through
nano-encapsulation,
controlled
delivery,
improvement
bioavailability.
This
review
explores
synergistic
potential
advanced
addressing
age-related
concerns.
It
highlights
key
developments
probiotic
formulations,
nano-based
delivery
systems,
combined
impact
on
health,
immunity,
neuroprotection.
convergence
represents
novel
transformative
approach
promoting
healthy
aging,
paving
way
for
innovative
interventions.
Language: Английский
Nano lipid-drug conjugates for the treatment of Alzheimer’s disease
Elsevier eBooks,
Journal Year:
2025,
Volume and Issue:
unknown, P. 237 - 291
Published: Jan. 1, 2025
Language: Английский
Emergence of Nanomaterials in the Management of Multiple Sclerosis
Shubhrat Maheshwari,
No information about this author
Amita Verma,
No information about this author
Aditya Singh
No information about this author
et al.
Published: Jan. 1, 2025
Language: Английский
Nanomedicine in Neuroprotection, Neuroregeneration, and Blood–Brain Barrier Modulation: A Narrative Review
Antea Kršek,
No information about this author
Ana Jagodic,
No information about this author
Lara Batičić
No information about this author
et al.
Medicina,
Journal Year:
2024,
Volume and Issue:
60(9), P. 1384 - 1384
Published: Aug. 24, 2024
Nanomedicine
is
a
newer,
promising
approach
to
promote
neuroprotection,
neuroregeneration,
and
modulation
of
the
blood–brain
barrier.
This
review
includes
integration
various
nanomaterials
in
neurological
disorders.
In
addition,
gelatin-based
hydrogels,
which
have
huge
potential
due
biocompatibility,
maintenance
porosity,
enhanced
neural
process
outgrowth,
are
reviewed.
Chemical
modification
these
especially
with
guanidine
moieties,
has
shown
improved
neuron
viability
underscores
tailored
biomaterial
design
applications.
further
discusses
strategies
modulate
barrier—a
factor
critically
associated
effective
delivery
drugs
central
nervous
system.
These
advances
bring
supportive
solutions
solving
conditions
innovative
therapies
for
their
treatment.
Nanomedicine,
as
applied
neuroscience,
presents
significant
leap
forward
new
therapeutic
that
might
help
raise
treatment
management
disorders
much
better
levels.
Our
aim
was
summarize
current
state-of-knowledge
this
field.
Language: Английский
Nanoparticle-Based Biomarkers for Neurological Disorders
Neelakanta Sarvashiva Kiran,
No information about this author
Chandrashekar Yashaswini,
No information about this author
Ankita Chatterjee
No information about this author
et al.
Nanotechnology in the life sciences,
Journal Year:
2025,
Volume and Issue:
unknown, P. 183 - 202
Published: Jan. 1, 2025
Language: Английский
Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs—Protocols and Advice for the FDA to Meet the ALS Act Vision
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(18), P. 10211 - 10211
Published: Sept. 23, 2024
Although
decades
of
intensive
drug
discovery
efforts
to
treat
neurodegenerative
disorders
(NDs)
have
failed,
around
half
a
million
patients
in
more
than
2000
studies
continue
being
tested,
costing
over
USD
100
billion,
despite
the
conclusion
that
even
those
drugs
which
been
approved
no
better
effect
placebo.
The
US
Food
and
Drug
Administration
(FDA)
has
established
multiple
programs
innovate
treatment
rare
diseases,
particularly
NDs,
providing
millions
funding
primarily
by
encouraging
novel
clinical
trials
account
for
issues
related
study
sizes
adopting
multi-arm
patient
dropouts.
Instead,
FDA
should
focus
on
primary
reason
failure:
poor
bioavailability
reaching
brain
(generally
0.1%
at
most)
due
blood–brain
barrier
(BBB).
There
are
several
solutions
enhance
entry
into
brain,
must
require
proof
significant
as
prerequisite
approving
Investigational
New
(IND)
applications.
also
rely
factors
other
biomarkers
confirm
efficacy,
these
rarely
relevant
use.
This
summarizes
how
used
NDs
can
be
made
effective
change
its
guidelines
IND
approval
drugs.
Language: Английский
Nanocrystals: a new herald for the management of Alzheimer’s disease
Journal of Dispersion Science and Technology,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 14
Published: Oct. 6, 2024
Alzheimer's
disease
(AD)
impairs
mental
development
and
interrupts
neurocognitive
functions
that
escalate
with
time
leading
to
death.
With
continuous
evolution
in
lifestyle
progression
of
age,
the
prevalence
AD
is
progressively
rising,
a
significant
economic
burden.
Thus,
effective
therapeutic
approaches
are
indeed
necessary
address
this
growing
concern.
Current
treatment
regimens
primarily
help
relieve
symptoms,
nevertheless,
nanotechnology-based
nerve
damage
can
be
regressed
along
reduction
inflammation
improved
brain
delivery.
Researchers
healthcare
professionals
working
diligently
develop
innovative
treatments
interventions
improve
quality
life
for
individuals
affected
by
AD.
This
review
paper
aims
provide
comprehensive
insights
on
pathogenesis,
FDA-approved
treatment,
recent
advancements
drug
therapy,
formulation
an
update
drugs
different
clinical
phases.
The
specifically
highlights
nanocrystals-based
formulations
their
ability
minimize
side
effects,
bioavailability,
pharmacodynamics
pharmacokinetics.
current
also
prospects
role
NCs
enabling
delivery
across
BBB
it
dives
deep
understand
its
potential
carve
out
directions
niche
area
treating
Language: Английский